SPPI Spectrum Pharmaceuticals, Inc.

9.700.84 (+9.48%)
Close: September 16, 2019

Quote

Previous Close
$9.70
Day Range
$8.76-$9.75
52 Week Range
$6.22-$21.80
Volume
1,259,247
Avg Volume
765,310
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$1.01B
Enterprise Value (EV)
$717.94M
PE Ratio
-
EV/EBITDA
-6.99
Price/Sales
8.43
Price/Book
3.56
PEG Ratio
0.02

Financials

Revenue
$109.33M
Gross Profit
$54.48M
EBITDA
-$102.77M
EPS, ttm
-$1.56
Profit Margin
-
Revenue/Employee
$465.25K
Next Earnings Date
11/11/2019 (55 days)
Debt to Equity
-
Debt
-
Cash
$203.99M
Net Debt
-

Performance

Beta
1.89
200 Day Moving Avg
$9.45
50 Day Moving Avg
$7.87
52 Week Change
-51.81%
YTD Change
5.47%
1 Month Change
10.61%
3 Month Change
8.18%
6 Month Change
-15.05%
1 Year Change
-55.99%
2 Year Change
62.09%
5 Year Change
42.73%

Share Count

Shares Outstanding
104.1M
Float
97.5M
Restricted Shares
6.6M
Restricted Shares, %
6.32%

Spectrum Pharmaceuticals, Inc. Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Joseph W. Turgeon

Website: http://www.sppirx.com

Description: Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development, and commercialization of pipeline of late-stage clinical and commercial products. It operates through the following brands: FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ, and EVOMELA. The company was founded in December 1987 and is headquartered in Henderson, NV.

Employees: 235